Tralokinumab for Eczema

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Psoriasis Treatment Center of Central New Jersey

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.

Eligibility Criteria

Adults over 18 with atopic dermatitis previously treated with dupilumab but needing alternative therapy can join. They must be in good health, not pregnant or lactating, and willing to use contraception. Excluded are those recently on systemic eczema therapies, non-compliant with Dupixent, using tanning/phototherapy, or have uncontrolled diseases.

Inclusion Criteria

I am not pregnant and will use birth control if there's a risk of getting pregnant.

I am eligible for treatment that affects my whole body.

I have been treated with dupilumab for my skin condition.

+3 more

Exclusion Criteria

I haven't used any systemic treatments for eczema in the last 4 weeks.

Patient non-compliant with Dupixent dosing based on investigator discretion

I haven't used tanning beds or undergone phototherapy in the last 4 weeks.

+4 more

Participant Groups

The trial tests Tralokinumab as an alternative for atopic dermatitis patients who didn't respond well to Dupilumab. Participants receive a starting dose of 600mg followed by 300mg every two weeks for six months to evaluate its effectiveness and safety.

1Treatment groups

Experimental Treatment

Group I: TralokinumabExperimental Treatment1 Intervention